Uhm, Joon H <br/><br/>
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.  [electronic resource] 

 -  International journal of radiation oncology, biology, physics  Jun 2011 
 - 347-53 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-355X 
<br/><br/><label>Standard No.: </label>10.1016/j.ijrobp.2010.01.070  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Brain Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant--methods<br/>Dexamethasone--administration & dosage<br/>Diarrhea--chemically induced<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Enzyme Activators--administration & dosage<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Gefitinib<br/>Gene Amplification--genetics<br/>Genes, erbB-1--genetics<br/>Glioblastoma--drug therapy<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Male<br/>Middle Aged<br/>Quinazolines--administration & dosage<br/>Young Adult